+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 13Years - 50Years
All Genders
ID07348601

Evaluating Safety and Effects of CSTI-500 for Prader-Willi Syndrome in a Dose-Escalation Study

Led by ConSynance Therapeutics · Updated on 2026-10-21

12

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying CSTI-500, an investigational oral drug, in people aged 13 to 50 with genetically confirmed Prader-Willi Syndrome PWS. This open-label, dose-escalation Phase 2 trial aims to evaluate the safety, tolerability, pharmacokinetics, and effectiveness of CSTI-500 in this population by adjusting doses based on blood levels. The study is led by ConSynance Therapeutics. Participants will receive increasing doses of CSTI-500 taken orally. The dose will be personalized using blood tests to measure the drug levels in the body. The trial includes different exposure groups with low, medium, and high target doses. The studys primary treatment period lasts up to 14 weeks. During the study, participants will have regular visits for assessments including laboratory tests, heart monitoring with ECGs, vital signs checks, and questionnaires focused on behavior and eating habits. Researchers will monitor treatment-emergent side effects and changes in clinical scores related to hyperphagia, behavior, and global impressions. The total study duration is about 12 to 14 weeks, with close safety monitoring and evaluation of drug levels throughout this time.

CONDITIONS

Brief Title

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

Research Team

B

Beth Mack

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here